Open AccessSARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
Author(s) -
Vimvara Vacharathit,
Sirawat Srichatrapimuk,
Suwimon Manopwisedjaroen,
Suppachok Kirdlarp,
Chanya Srisaowakarn,
Chavachol Setthaudom,
Nanthicha Inrueangsri,
Prapaporn Pisitkun,
Mongkol Kunakorn,
Suradej Hongeng,
Somnuek Sungkanuparph,
Arunee Thitithanyat
Publication year - 2021
Publication title -
international journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 89
eISSN - 1878-3511
pISSN - 1201-9712
DOI - 10.1016/j.ijid.2021.09.021
Subject(s) - covid-19 , pneumonia , virology , neutralizing antibody , medicine , antibody , cytokine , immunology , outbreak , infectious disease (medical specialty) , disease
As coronavirus disease 2019 (COVID-19) rages on worldwide, there is an urgent need to characterize immune correlates of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify immune determinants of COVID-19 severity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom